Christopher L. Brooks
Plus aucun poste en cours
Historique de carrière de Christopher L. Brooks
Anciens postes connus de Christopher L. Brooks
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2010 | - |
Formation de Christopher L. Brooks
| State University of New York at Binghamton | Undergraduate Degree |
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
Opérationnelle
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Consumer Services | 3 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
- Bourse
- Insiders
- Christopher L. Brooks
- Expérience
